|
|
| | 1646862-09-0 Basic information |
| Product Name: | 1646862-09-0 | | Synonyms: | 5-[[[(2,4-Difluorophenyl)methyl]amino]carbonyl]-1,4-dihydro-3-methoxy-4-oxo-1-(2-oxoethyl)-2-pyridinecarboxylic Acid Methyl Ester;2-Pyridinecarboxylic acid, 5-[[[(2,4-difluorophenyl)methyl]amino]carbonyl]-1,4-dihydro-3-methoxy-4-oxo-1-(2-oxoethyl)-, methyl ester;D65-B interconversion impurity;Cabotegravir Impurity 18 | | CAS: | 1646862-09-0 | | MF: | C18H16F2N2O6 | | MW: | 394.33 | | EINECS: | | | Product Categories: | | | Mol File: | 1646862-09-0.mol |  |
| | 1646862-09-0 Chemical Properties |
| Boiling point | 604.8±55.0 °C(Predicted) | | density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere | | solubility | Dichloromethane; | | form | Solid | | pka | 10.69±0.40(Predicted) | | color | Yellow |
| | 1646862-09-0 Usage And Synthesis |
| Uses | 5-[[[(2,4-Difluorophenyl)methyl]amino]carbonyl]-1,4-dihydro-3-methoxy-4-oxo-1-(2-oxoethyl)-2-pyridinecarboxylic Acid Methyl Ester is an intermediate in the synthesis of Cabotegravir-d3 (C050102), which is the labelled form of Cabotegravir (C050100). Cabotegravir is a long acting HIV-1 integrase inhibitor with action against a broad range of HIV subtypes. |
| | 1646862-09-0 Preparation Products And Raw materials |
|